Absence of γ-Interferon–inducible Lysosomal Thiol Reductase in Melanomas Disrupts T Cell Recognition of Select Immunodominant Epitopes
暂无分享,去创建一个
P. Cresswell | H. Zarour | M. Marić | J. Blum | U. Phan | J. Hawes | M. A. Haque | Ping Li | S. Jackson
[1] Richard A. Flavell,et al. Defective Antigen Processing in GILT-Free Mice , 2001, Science.
[2] V. Brusic,et al. gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells , 2001, British Journal of Cancer.
[3] J. Blum,et al. Cysteinylation of MHC Class II Ligands: Peptide Endocytosis and Reduction Within APC Influences T Cell Recognition1 , 2001, The Journal of Immunology.
[4] J. Trapani,et al. A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.
[5] C. Nelson,et al. Structural and Functional Consequences of Altering a Peptide MHC Anchor Residue1 , 2001, The Journal of Immunology.
[6] R. Dwek,et al. Folding and Maturation of Tyrosinase-related Protein-1 Are Regulated by the Post-translational Formation of Disulfide Bonds and by N-Glycan Processing* , 2000, The Journal of Biological Chemistry.
[7] A. van Elsas,et al. Costimulatory wars: the tumor menace. , 2000, Current opinion in immunology.
[8] V Brusic,et al. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. , 2000, Cancer research.
[9] B. Seliger,et al. Antigen-processing machinery breakdown and tumor growth. , 2000, Immunology today.
[10] P. Cresswell,et al. Gamma-interferon-inducible lysosomal thiol reductase (GILT). Maturation, activity, and mechanism of action. , 2000, The Journal of biological chemistry.
[11] P. Cresswell,et al. Gamma-Interferon-inducibleLysosomal Thiol Reductase (GILT) , 2000, The Journal of Biological Chemistry.
[12] J. Blum,et al. Endocytic Recycling is Required for the Presentation of an Exogenous Peptide via MHC Class II Molecules , 2000, Traffic.
[13] E. Sercarz,et al. Cutting Edge: Introduction of an Endopeptidase Cleavage Motif into a Determinant Flanking Region of Hen Egg Lysozyme Results in Enhanced T Cell Determinant Display1 , 2000, The Journal of Immunology.
[14] Stork Wj,et al. Melanoma antigens recognised by CD8+ and CD4+ T cells. , 2000 .
[15] M. Brady,et al. Restoration of Alloreactivity of Melanoma by Transduction With B7.1 , 2000, Journal of immunotherapy.
[16] C. Watts,et al. Antigen Traffic Pathways in Dendritic Cells , 2000, Traffic.
[17] P. Cresswell,et al. Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT). , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[18] V. Brusic,et al. Melan-A/MART-151–73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells , 2000 .
[19] J. Kirkwood,et al. Dendritic Cell/Peptide Cancer Vaccines: Clinical Responsiveness and Epitope Spreading , 2000, Immunological investigations.
[20] D. Zaller,et al. Role of APC in the selection of immunodominant T cell epitopes. , 1999, Journal of immunology.
[21] J. Yewdell,et al. Modification of Cysteine Residues In Vitro and In Vivo Affects the Immunogenicity and Antigenicity of Major Histocompatibility Complex Class I–restricted Viral Determinants , 1999, The Journal of experimental medicine.
[22] Ferry Ossendorp,et al. CD4 T Cells and Their Role in Antitumor Immune Responses , 1999, The Journal of experimental medicine.
[23] Matteo Bellone,et al. Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11 , 1999, The Journal of experimental medicine.
[24] Parkhurst,et al. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. , 1999, Journal of immunology.
[25] D. Pardoll,et al. The role of CD4+ T cell responses in antitumor immunity. , 1998, Current opinion in immunology.
[26] J. Shabanowitz,et al. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. , 1998, Journal of immunology.
[27] P. Hersey,et al. Interferon-resistant Human Melanoma Cells Are Deficient in ISGF3 Components, STAT1, STAT2, and p48-ISGF3γ* , 1997, The Journal of Biological Chemistry.
[28] W. Heath,et al. Induction of a CD8+ Cytotoxic T Lymphocyte Response by Cross-priming Requires Cognate CD4+ T Cell Help , 1997, The Journal of experimental medicine.
[29] J. Ting,et al. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[30] C. Leclerc,et al. Parameters affecting the immunogenicity of recombinant T cell epitopes inserted into hybrid proteins. , 1997, Human immunology.
[31] N. Leister,et al. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. , 1997, Journal of immunological methods.
[32] A. Agulnik,et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. , 1997, Immunity.
[33] J. Bryant,et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. , 1996, The Journal of clinical investigation.
[34] A Sette,et al. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes , 1996, The Journal of experimental medicine.
[35] S. H. van der Burg,et al. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumors , 1995, European journal of immunology.
[36] J. Becker,et al. Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma. , 1993, International immunology.
[37] G. Winter,et al. Antibody framework residues affecting the conformation of the hypervariable loops. , 1992, Journal of molecular biology.
[38] E. Unanue,et al. Reduction of disulfide bonds within lysosomes is a key step in antigen processing. , 1991, Journal of immunology.
[39] P. Jensen. Reduction of disulfide bonds during antigen processing: evidence from a thiol-dependent insulin determinant , 1991, The Journal of experimental medicine.
[40] J. Hansen,et al. Structural requirements for recognition of the HLA-Dw14 class II epitope: a key HLA determinant associated with rheumatoid arthritis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[41] D. Guerry,et al. Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early, disease. , 1989, Journal of immunology.
[42] N. Shastri,et al. The choice between two distinct T cell determinants within a 23-amino acid region of lysozyme depends on their structural context. , 1986, Journal of immunology.
[43] N. Shastri,et al. Amino acid residues distinct from the determinant region can profoundly affect activation of T cell clones by related antigens. , 1986, Journal of immunology.
[44] A. Lazaris,et al. Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma , 2004, Virchows Archiv.
[45] V. Brusic,et al. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[46] C. Watts,et al. Capture and processing of exogenous antigens for presentation on MHC molecules. , 1997, Annual review of immunology.
[47] A. Miller,et al. Dominance and crypticity of T cell antigenic determinants. , 1993, Annual review of immunology.
[48] T. Kageshita,et al. [Expression of HLA-class II antigens in malignant melanoma]. , 1990, Nihon Hifuka Gakkai zasshi. The Japanese journal of dermatology.